BRCA1 and neoplasm: In a mouse model of high-grade plasmacytoid ovarian cancer driven by concomitant deletion of p53, Brca1 and c-Myc overexpression, olaparib induced an increase in PD-L1 expression in tumor cells by activating the interferon gene stimulating factor (STING) pathway (Ding et al. 2018).